Pharnext’s PXT3003 Featured at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 2017 Annual M...
September 07 2017 - 10:45AM
Business Wire
Regulatory News:
Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA),
a biopharmaceutical company pioneering a new approach to the
development of innovative drugs based on the combination and
repositioning of known drugs, today announced that data related to
PXT3003, the Company’s lead PLEODRUG™, in development for the
treatment of Charcot-Matrie-tooth type 1A (CMT1A) disease will be
presented in a poster viewing session at the AANEM 2017 Annual
Meeting, September 13-16, in Phoenix, Arizona, U.S.
Details are as follow:
Date & Time Title
September14 -15, 2017All day
Poster #90: “A multicenter,
double-blind, placebo-controlled, pivotal Phase III study(PLEOCMT)
of a fixed combination of baclofen, naltrexone and sorbitol
(PXT3003), for thetreatment of CMT1A” S. Attarian et al.
The abstract is available online at :
http://www.aanem.org/Meetings/Annual-Meeting/Abstracts
About PXT3003
PXT3003, Pharnext’s lead PLEODRUG™ in development for the
treatment of Charcot-Marie-Tooth type 1A disease (CMT1A), is a
novel, synergistic, low-dose combination of baclofen, naltrexone,
and D-sorbitol formulated as an oral solution given twice-daily.
PXT3003 has multiple main mechanisms of action: a synergistic
inhibition of PMP22 gene overexpression associated with myelination
improvement, direct nerve protection and additional positive
effects on other cellular types: muscle cells, neuromuscular
junctions and immune cells. PXT3003 obtained positive results in a
Phase II clinical trial in 80 adult patients with CMT1A. In 2014,
the EMA and FDA granted orphan drug designation to PXT3003 for the
treatment of CMT1A in adults. An international pivotal Phase III
trial (PLEO-CMT) in over 300 adult patients with CMT1A is now
underway at 30 sites across Europe, the U.S. and Canada.
About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company
founded by renowned scientists and entrepreneurs including
Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has
two lead products in clinical development. PXT3003 is currently in
an international Phase 3 trial for the treatment of
Charcot-Marie-Tooth disease type 1A and benefits from orphan drug
status in Europe and the United States. PXT864 has generated
positive Phase 2 results in Alzheimer’s disease. Pharnext is the
pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company
identifies and develops synergic combinations of repositioned drugs
at new optimal lower doses. These PLEODRUG™ offer several key
advantages: efficacy, safety and intellectual property including
several product or composition of matter patents already granted.
The Company is supported by a world-class scientific team.
The company Pharnext is listed on Euronext Growth Stock Exchange
in Paris (ISIN code: FR00111911287).For more information, visit
www.pharnext.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170907006130/en/
PharnextXavier Paoli, +33 (0)1 41 09 22 30Chief
Commercial Officercontact@pharnext.comorInvestor Relations
(Europe)MC Services AGAnne Hennecke, +49 211 529252
22anne.hennecke@mc-services.euorMedia Relations
(Europe)ALIZE RPCaroline CarmagnolMargaux Pronost+33 (0)1 44 54
36 64pharnext@alizerp.comorPharnextRené Goedkoop, +33 (0)1
41 09 22 30Chief Medical Officercontact@pharnext.comorInvestor
Relations (U.S.)Stern Investor Relations, Inc.Matthew Shinseki,
+1 212-362-1200matthew@sternir.comorMedia Relations
(U.S.)Russo PartnersTony RussoScott
Santiamotony.russo@russopartnersllc.comscott.santiamo@russopartnersllc.com+1
212-845-4251+1 718-344-5843orFinancial Communication
(France)New CAPEmmanuel Huynh, +33 (0)1 44 71 20
40pharnext@newcap.eu
Pharnext (EU:ALPHA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pharnext (EU:ALPHA)
Historical Stock Chart
From Apr 2023 to Apr 2024